Observational Study Towards the Impact of Newly Started Treatment in MDS on QoL
- Status
- COMPLETED
- Phase
- N/A
Clinical Trials Related to Myelodysplastic Syndromes
Related studies linked through entity extraction aliases.
A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
- Status
- WITHDRAWN
- Phase
- PHASE2
A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea
- Status
- COMPLETED
- Phase
- N/A
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
- Status
- RECRUITING
- Phase
- PHASE1
Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy
- Status
- COMPLETED
- Phase
- N/A
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
- Status
- UNKNOWN
- Phase
- N/A
Combining Active and Passive DNA Hypomethylation
- Status
- RECRUITING
- Phase
- PHASE2
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant
- Status
- COMPLETED
- Phase
- PHASE2
A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).
- Status
- TERMINATED
- Phase
- PHASE2
ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE1
CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS
- Status
- TERMINATED
- Phase
- PHASE2
A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Status
- COMPLETED
- Phase
- PHASE1
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
- Status
- COMPLETED
- Phase
- NA
An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion
- Status
- COMPLETED
- Phase
- PHASE2
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2